GU Cancers 2023 | TRISST: cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma

Robert Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK, discusses the cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma as evaluated using the data from the Phase III TRISST (NCT00589537) trial. 669 men were randomized to 4 surveillance groups undergoing 7 CTs over 5 years, 3 CTs over 3 years, 7 MRIs, or 3 MRIs of the retroperitoneum. Resource use and health outcomes data on each patient were collected at baseline and over a period of 6 years after randomization. Overall, the study showed differences exist in total costs and quality of life between different strategies. A 7 scan MRI schedule yielded more health benefits than other strategies, but at higher costs. Considering possible capacity constraints with MRI, the reduced radiation exposure relative to CT, and non-inferiority for clinical outcomes in the primary analysis, a 3 scan MRI schedule may be the superior option to replace current CT-based longer surveillance practice. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.